Children With Cancer Have Greater Risk of Severe COVID-19 Outcomes
About 20% of pediatric cancer patients who developed COVID-19 had severe or critical disease.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Responses to COVID-19 Vaccines in Cancer Patients: Impact of Tumor and Treatment Type
Most patients with solid tumors demonstrate immune responses to COVID-19 vaccines, but a subset of patients do not. -
Lymphoma Patients Show Continued Cognitive Decline After Chemotherapy
Lymphoma patients displayed cognitive decline 6 months after chemotherapy, both by objective assessment and self-report. -
Responses to COVID-19 Vaccines Vary in Patients With Hematologic Malignancies
Responses varied according to patients’ cancer type, the anticancer treatment they received, and which vaccine was used. -
Current and Emerging Therapies for Relapsed and Refractory Multiple Myeloma
Experts review approved therapies and treatments still under investigation.
HEMATOLOGIC CANCER NEWS
Tumor Microenvironment Cellular Makeup May Predict Nivolumab Response for Patients With Hodgkin Lymphoma
R-NPLD Combination Treatment Safe and Effective for Patients With Diffuse Large B-Cell Lymphoma
Orelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Technology-Based Psychosocial Program Effective for Adolescent Leukemia Survivors
Interleukin-6 Levels May Predict PFS in Relapsed/Refractory Hodgkin Lymphoma Treated With Nivolumab
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
Loading... 
Loading...